This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add CRISPR Stock to Your Portfolio
by Zacks Equity Research
CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.77, moving -1.62% from the previous trading session.
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $287.24, marking a +0.13% move from the previous day.
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.
Vertex (VRTX) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y
by Zacks Equity Research
Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
by Zacks Equity Research
JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog.
Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX).
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.
Here's What Key Metrics Tell Us About Vertex (VRTX) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.27, marking a -1.8% move from the previous day.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $319.98, marking a -0.46% move from the previous day.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH